Cambridge, UK, 28 July 2026 - One Nucleus expands its portfolio of member benefits through o2h co-discovery bringing discounted exclusive access for eligible One Nucleus members to specialist in-vitro ADME and DMPK services designed to support early-stage drug discovery.

The initiative has been developed in response to the challenges many emerging biotech companies face in today's funding environment, where access to high-quality preclinical data is increasingly important for understanding compound behaviour, progressing programmes, raising investment and making confident business decisions. By introducing this new member-exclusive programme, One Nucleus continues its commitment to providing opportunities of practical support that helps their member companies accelerate scientific innovation while reducing barriers to early-stage research.

Through the collaboration, members will have access to a flexible, points-based programme that enables them to undertake a range of in-vitro ADME and DMPK studies through o2h co-discovery. 

Supernova eligible members will be able to access ADME/DMPK services valued at $5000 for a participation fee of $1000. The credits can be used across a range of in vitro assays, giving companies the flexibility to select the studies most relevant to their projects. Further information, including programme guidance, eligibility criteria and application details, will be accessed through the One Nucleus member portal.

Developed specifically for the One Nucleus community, this initiative reflects the organisation's wider commitment to connecting members with trusted partners, specialist expertise and practical resources that support both scientific progress and business growth.

Tony Jones, Chief Executive of One Nucleus, said:

"One Nucleus is committed to creating opportunities that help our members innovate, collaborate and grow. As drug discovery becomes increasingly multidisciplinary, access to the right scientific expertise at the right time can make a significant difference. We're delighted to work with o2h co-Discovery to introduce a practical member benefit that supports our community in progressing promising therapeutic programmes."

Prashant Shah, CEO, o2h co-Discovery and said:

"We hope that Supernova is helpful to innovators generating the data they need to move promising programmes forward. We're delighted to work alongside One Nucleus in supporting companies that are advancing the next generation of therapeutic innovation."

About One Nucleus

One Nucleus's vision is to supercharge bio-innovation. 

Its mission is to inspire, inform, and implement by connecting bio-innovation leaders and their companies with knowledge, investment, and deal-flow opportunities in a capital-efficient way, supporting organisations from start-up through to exit. 

As a not-for-profit life science membership organisation, One Nucleus brings together stakeholders from across the sector to help them achieve their aspirations on the global stage.

About o2h Discovery

At o2h co-discovery, we seed new ideas in life science. We have a proprietary operating system for fast tracking new ideas to a development candidate. The core is an integrated multi-modality drug discovery platform that combines novel capability with strategic partners embedded in AI enabled backbone to create a unique workflow. We are an insight driven team based out of Cambridge, UK/USA and Ahmedabad, India.  

For more information, visit: www.o2hdiscovery.co.